Drug Trial Radar · NCT00582582
Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Dec 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
70
Actual
Start
Apr 2002
Primary completion
Not stated
Study completion Apr 2007
Sponsor
- Lead sponsor
- University of Wisconsin, MadisonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi; Genzyme, a Sanofi Company
- First posted
- Dec 28, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to find out the toxicities of doxercalciferol given in combination with docetaxel (Taxotere®), as well as to see how well this combination works in the treatment of prostate cancer.
Conditions
- Prostate Cancer
Interventions
Docetaxel plus doxercalciferolDrug
Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
Docetaxel plus placeboDrug
Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: At 12 weeks on study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.